The StrAU Nuclear Technology for Medicine combines the University groundwork in the field of nuclear technology for the diagnosis and therapy of cancer. In addition, the StrAU solves the problem of internationalization of academic programs in this field and strives to achieve new results in the areas of generation of high-intensity fluxes of ionizing radiation and nuclear medicine. The StrAU results contribute to solution of a crucial international problem that is increasing duration and quality of life.
The structural divisions of the StrAU:
- Applied Physics;
- General Physics;
- Physical and Energy Installations;
- Technical Physics;
- Higher Mathematics and Mathematical Physics;
- Laboratory for Biomedical Isotopes;
- Nuclear Research Reactor.
Key academic programs:
- Nuclear Physics and Technologies
- Electronics and Automation of Physical Installations
The main areas of research and engineering projects:
- Creation of radiopharmaceutical based on labeled 99mTc doxorubicin for visualization of cancer and prognosis of chemotherapy effectiveness;
- Development of software and hardware complex for analysis of biological objects based on small betatrons and generators of quasi-monochromatic X-ray radiation;
- Development of nonperturbing diagnostic methods of parameters of charged particle beams in accelerating complexes based on polarized radiation.
Expected results of the StrAU:
- Training of highly qualified specialists in the field of nuclear medicine;
- Tandem target RFP based on 99mTc / 186Re isotopes for early diagnosis and personalized therapy using monoclonal antibodies;
- Hardware complex based on small betatrons for intraoperative therapy of malignant neoplasms and methods of its planning, taking into account glucose metabolism in tumor tissue;
- Equipment and methods for neutron-capture and photon-capture therapy of rare types of brain cancer (glioblastoma) using effective radiosensitizers based on gadolinium.
Results achieved in 2016:
- For the first time in the world, the University obtained a nanocolloidal preparation based on aluminum oxide labeled with the isotope technique-99, necessary for the accurate diagnosis of oncological diseases that means detection of watchdog lymph nodes.
- Conducted preliminary tests of the functional suitability of technetium-labeled mini-antibody on positive and negative HER2 / neu cell lines of mammary adenocarcinoma.
- Carried out screening of Doxorubicin 99mTc samples quality according to the nature of scintigraphic images during its distribution in the body of laboratory animals. The conducted research projects demonstrated significantly (by 9-10 times) higher rate of accumulation of radiopharmaceuticals in the malignant tumor cells with overexpression of HER2 /neu comparing to the control group.
- Developed a technology for production of a lyophilized reagent with an extended shelf life for following preparation of dosage form of the radiopharmaceutical 1-thio-D-glucose, 99mTc. One developed and tested methods for the medicine quality control by its main components and a draft specification for its production was proposed.
- Designed an original method for synthesizing bifunctional chelator and a method of attaching synthesized chelator to a mini-antibody.
- Сarried out research on the evaluation of functional suitability of the glucose derivative of 1-thio-D-glucose;
- On the basis of the first horizontal experimental channel of the reactor, one created a protective box with a set of devices for conducting studies in the field of neutron-capture therapy of malignant tumors. The University researchers used experimental methods to study nuclear physical characteristics of neutron field of the extracted neutron beam. Through calculation one attempts optimizing nuclear-physical characteristics of the extracted neutron beam in order to obtain maximum neutron flux density of the required range.
Partners: Rosatom State Atomic Energy Corporation, Roscosmos State Corporation for Space Activities, State Corporation Rostec, Rosenergoatom, TVEL Fuel Company (nuclear fuel cycle company), Universite Paris-Saclay (France), Technical University of Munich (Germany); European Organization for Nuclear Research (Switzerland), Siberian State Medical University, and National Institute of Nuclear Physics (Italy).